Table 2 Comparisons of clinical characteristics of pediatric patients with severe ADVP after IMV in the PIBO and non-PIBO groups
Variables | Non-PIBO group (n = 33) | PIBO group (n = 33) | P Value |
|---|---|---|---|
Characteristic | |||
 Male, n (%) | 21 (63.6) | 29 (87.9) | 0.02 |
 Age [M (P25-P75)]/(months) | 12 (8–24) | 12 (10–22) | 0.88 |
Age group (months), n (%) | |||
 < 6 | 3 (9.1) | 2 (6.1) | 0.64 |
 6–24 | 24 (72.7) | 28 (84.8) | 0.23 |
 25–36 | 6 (18.2) | 3 (9.1) | 0.28 |
Significant comorbidities, n (%) | |||
 Premature birth | 5 (15.2) | 3 (9.1) | 0.45 |
 A history of wheezing | 15 (45.5) | 14 (42.4) | 0.80 |
 Congenital heart disease | 5 (15.2) | 3 (9.1) | 0.45 |
 Allergic constitution [n (%)] | 10 (30.3) | 12 (36.4) | 0.1 |
Sigs and symptoms | |||
 Median duration of hospitalization [M (P25-P75)]/d | 24 (17–27) | 27 (23–32) | 0.01 |
 Duration of fever [M (P25-P75)]/d | 20 (15–22) | 23 (20–31) | 0.00 |
 Wheezing [n (%)] | 19 (57.6) | 10 (30.3) | 0.03 |
Laboratory characteristic | |||
 WBC [M (P25-P75)]// × 109 L−1 | 6.5 (4.2–9.9) | 6.4 (4.4–10.6) | 0.57 |
 N% [M (P25-P75)]/% | 62.5 (51.1–70.4) | 64.3 (47.1–71.1) | 0.33 |
 Hypohemia, n (%) | 24 (72.7) | 28 (84.8) | 0.23 |
 PLT [M (P25-P75)]/ × 109 L−1 | 285 (197–445) | 311 (189–428) | 0.84 |
 CRP [M (P25-P75)]/mg·L−1 | 8.5 (3.1–23.3) | 9 (3.1–18.1) | 0.36 |
 PCT [M (P25-P75)]/ng·mL−1 | 0.9 (0.06–1.9) | 1.0 (0.42–1.91) | 0.28 |
 LDH [M (P25-P75)]/U·L−1 | 544 (351–890) | 687 (464–968) | 0.29 |
 Fig [M (P25-P75)]/mg·dL−1 | 2.1 (1.6–2.9) | 2.3 (1.6–3.0) | 0.29 |
 DD [M (P25-P75)]/mg·L−1 | 2.2(1.6–3.1) | 2.3 (1.7–2.9) | 0.14 |
 CK-MB [M (P25-P75)]/ng·mL−1 | 42 (27–56) | 36 (28–45) | 0.48 |
 ALT [M (P25-P75)]/U·L−1 | 40.8 (18.4–75.4) | 32.4 (20.2–70.8) | 0.33 |
 AST [M (P25-P75)]/U·L−1 | 84 (60–168) | 98 (70.3–142) | 0.30 |
 Mixed infection [n (%)] | 29(87.9) | 33 (100) | 0.04 |
 Bacterial coinfection [n (%)] | 18 (54.5) | 22 (66.7) | 0.31 |
 MP-coinfection [n (%)] | 10 (30.3) | 13 (41.2) | 0.44 |
 Virus-coinfection [n (%)] | 12 (36.4) | 24 (72.7) | 0.11 |
 Fungi coinfection [n (%)] | 14 (42.4) | 25 (75.8) | 0.006 |
 ADV load from BALF, log10 copies/mL | 6.0 (5–6.9) | 7.1 (6.4–8.1) | 0.002 |
Humoral immunity [M (P25-P75), %] | |||
 IgG [M (P25-P75)]/g·L−1 | 8.4 (6.9–13.4) | 8.0 (6.7–10.1) | 0.24 |
 IgA [M (P25-P75)]/g·L−1 | 0.8 (0.6–1.1) | 0.8 (0.6–1.2) | 0.78 |
 IgM [M (P25-P75)]/g·L−1 | 0.7 (0.3–1.0) | 0.7 (0.4–1.02) | 0.54 |
Cellular immunity [M (P25-P75), %] | |||
 CD3+  | 50.4 (43.1–57.7) | 50.5 (40.4–59.4) | 0.76 |
 CD3+ CD4+  | 20.0 (15.7–30.7) | 22.4 (18.7–27.8) | 0.59 |
 CD3+ CD8+  | 21.5 (16.4–24.8) | 20.2 (15.6–28.7) | 0.65 |
Radiological characteristics [n (%)] | |||
 Lung consolidation | 19 (57.6) | 25 (75.8) | 0.12 |
 Pleural effusion | 5 (15.2) | 7 (21.2) | 0.52 |
 Associated multy organ dysfunction, n (%) | 30 (90.9) | 33 (100) | 0.08 |
Treatment, n (%) | |||
 Length of IMV[M(P25-P75)]/d | 8 (7–12) | 11 (9–14) | 0.03 |
 CRRT, n (%) | 4 (12.1) | 4 (12.1) | 1.00 |
 ECMO, n (%) | 0 (0) | 1 (3.0) | 0.31 |
 Corticosteroids | 23 (69.7) | 28 (84.8) | 0.14 |
 IV immunoglobulin | 29 (87.9) | 31 (93.9) | 0.39 |
 Tracheoscopy intervention therapy | 14 (42.4) | 21 (63.6) | 0.08 |
 Death | 0 | 1 | 0.31 |